Historically, vitamin K antagonists have been the only class of oral anticoagulants available.
INTRODUCTION
Anticoagulation is a critical component in the management of venous thromboembolism (VTE) and atrial fibrillation. Venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary embolism (PE), has an annual incidence rate of approximately 1 per 1000 people in the general population. Furthermore, VTE is the third most common acute cardiovascular disorder after myocardial infarction and stroke, affecting approximately 900,000
persons in the United States annually [1, 2] . Atrial fibrillation is the most prevalent cardiac arrhythmia, affecting over 2.2 million people in the United States and 4.5 million people in the European Union [3] .
Vitamin K antagonists (VKAs) have been the standard of care for the prevention and treatment of VTE, and stroke prevention in atrial fibrillation patients. Prior to 2009, the only oral anticoagulant available in the United States was warfarin. Three months of warfarin for idiopathic VTE resulted in a 95% reduction in recurrent thromboembolism [4] . Warfarin has been found to reduce the risk of stroke by 64% compared to placebo in patients with atrial fibrillation [5] . The rate of major bleeding with warfarin in the setting of venous thromboembolism has been estimated to be approximately 6.5% per year, with a range of 3% in low-risk patients to 30% in high-risk patients [6] . In the setting of atrial fibrillation, the rate of major bleeding has been estimated to be approximately 2.3% per year [7] . The limitations of VKAs are well documented, including a narrow therapeutic window that requires monitoring, variable therapeutic response, delayed onset and offset of action, dose adjustments, food and drug interactions, and risk for bleeding.
In 2009, the first oral factor IIa (thrombin) inhibitor, dabigatran, was approved by the United States Food and Drug Administration (FDA) for the prevention of stroke in the setting of non-valvular atrial fibrillation (NVAF). Two oral factor Xa (fXa) inhibitors, rivaroxaban and apixaban, were subsequently FDA-approved for the same indication (Table 1 ) [8] [9] [10] [11] .
Eventually, these agents were all approved for the prevention and treatment of VTE as well. These non-vitamin K oral anticoagulants (NOACs) have challenged the previously accepted realities of therapeutic monitoring, bridging regimens, and dietary modifications.
However, these agents are not without their clinical limitations. A number of pharmacokinetic drug interactions still must be considered for appropriate use and dosing.
Additionally, apixaban and dabigatran require twice-daily dosing, which may negatively impact patient adherence. These NOACs have been found to be at least as safe as warfarin.
While approved doses of rivaroxaban and dabigatran have resulted in similar rates of major bleeds compared to VKAs, apixaban is associated with a reduced risk [12] . The NOACs have resulted in a significant reduction in intracranial hemorrhage compared to VKAs, however several of these agents have been associated with an increase in gastrointestinal bleeding [13] . With these limitations in mind, the search for an optimal oral anticoagulant continues. Edoxaban (Savaysa), a new fXa inhibitor, was FDA-approved in 2015 and appears poised to address some of these practical concerns.
Compliance with Ethics Guidelines
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EDOXABAN Pharmacology
Edoxaban, like rivaroxaban and apixaban, is a selective fXa inhibitor. Edoxaban inhibits free fXa without the need of antithrombin (Fig. 1 ).
This inhibition of fXa in the coagulation cascade leads to decreased thrombin generation, and therefore, a reduction in thrombus formation and progression. The reduction in thrombin also results in an indirect inhibition of platelet aggregation. Changes in the prothrombin time (PT), international normalized ratio (INR), and activated partial thromboplastin time (aPTT) may be observed in patients on therapeutic edoxaban doses. However, these changes tend to be small, unpredictable, and highly variable, so clinicians should not use these markers to monitor the anticoagulant effects or titrate the dose of edoxaban [14] .
Pharmacokinetics
The pharmacokinetics of edoxaban have been shown to be dose dependent following single doses up to 150 mg and repeated doses up to 120 mg in healthy subjects [15, 16] . procoagulant properties due to a mutation in Fig. 1 In a, FXa forms a complex with FVa to allow for conversion of prothrombin to thrombin. In b, FXa inhibitor binds to FXa, preventing the conversion of prothrombin to thrombin. In c, FXa inhibitor binds to andexanet alfa rather than FXa, allowing for formation of thrombin. Gla Gamma-carboxyglutamic acid the serine residue of the amino acid structure.
To prevent competition between this inactive rFXa and active fXa molecules in the coagulation cascade, andexanet alfa lacks a membrane-binding c-carboxyglutamic acid domain ( Fig. 1) . Therefore, andexanet alfa has the capacity to bind direct fXa inhibitors without interfering with the coagulation cascade [20, 21] . Several phase 1 and phase 2 trials have shown promise for andexanet alfa's ability to reverse the effects of various fXa inhibitors [20] . One study specific to edoxaban
showed that a single 60-mg dose of edoxaban was reversed 52% following a 600 mg bolus of andexanet and by 73% following an 800-mg bolus. Both bolus doses were followed by a continuous andexanet infusion of 8 mg/min for 1 h. Within 2 h of stopping the andexanet infusion, anti-fXa levels returned to those measured in the group receiving placebo 
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Rare Rare CYP cytochrome p450, h hours, P-gp P-glycoprotein, T 1/2 half-life, T max time to maximum concentration, VKOR vitamin K epoxide reductase infusions [22] . Phase 3 trials investigating this agent for reversal of NOACs are currently underway [23, 24] . Another promising antidote under development is aripazine (PER977). This small molecule binds non-covalently to and inhibits the activity of both direct and indirect anticoagulants, including both oral and parenteral agents. Unlike andexanet, which is specific to fXa inhibitors, aripazine has been shown to have effects on dabigatran as well [20] .
Specific to edoxaban, a phase 1 trial was conducted in which 80 healthy volunteers received an intravenous bolus dose of 5-300 mg aripazine. In the patients who were also pretreated with 60 mg edoxaban, the whole blood clotting time was normalized following a single 300-mg bolus dose of aripazine. The anticoagulant effects of aripazine remained stable over a 24-h period [25] . An additional phase 2 trial investigating this agent for reversal of edoxaban is currently underway [26] .
Drug Interactions
One benefit of the NOACs is the potential for fewer drug-drug interactions. However, several clinically significant drug interactions are worth noting with edoxaban. The majority of pharmacokinetic drug interactions result from inhibition or induction of the P-glycoprotein (P-gp) efflux transporter which is responsible for intestinal transport of edoxaban [27] [28] [29] [30] . One study evaluated the effects of various cardiovascular agents on the pharmacokinetics of edoxaban (Table 3 ) [27] [28] [29] . Other drugs with pharmacokinetic interactions with edoxaban are worth noting. Ketoconazole, erythromycin, and cyclosporine also inhibit P-gp and concomitant use with edoxaban resulted in significant increases in Cmax and AUC.
Rifampin, a P-gp inducer, when administered along with edoxaban resulted in significantly lower AUC [14] . Based on these interactions, patients taking protease inhibitors or cyclosporine were excluded from phase III clinical trials evaluating edoxaban [28, 29] . The Hokusai-VTE trial also required a dose reduction of edoxaban during any acute use of macrolide antibiotics, ketoconazole, or itraconazole. Chronic use of these antibiotics was not allowed [29] . The use of anticoagulants, antiplatelet drugs, and/or thrombolytics with edoxaban should be avoided due to the potential for increased risk of bleeding [11] . Patients receiving dual antiplatelet therapy were not enrolled in phase III clinical trials evaluating edoxaban [28, 29] . Low-dose aspirin, thienopyridines, and non-steroidal anti-inflammatory drugs were allowed in clinical trials evaluating edoxaban, and concomitant use of these medications resulted in increased rates of clinically relevant bleeding
[11].
Atrial Fibrillation
Edoxaban was studied in a phase II trial for the prevention of stroke and systemic embolism in patients with NVAF [31] . This multicenter trial randomized 1146 patients to one of five treatment groups including edoxaban 30 mg PO daily (n = 235), 30 mg PO twice daily (n = 244), 60 mg PO daily (n = 234), 60 mg PO twice daily (n = 180), or warfarin titrated to a goal INR 2-3 (n = 250). While the primary outcome was the occurrence of major and/or clinically relevant non-major bleeding, the rate of stroke and systemic embolism was collected. Approximately 63% of patients had a CHADS2 score of 2 in each arm. The presence of stroke, TIA, or systemic embolism was low and no statistical differences were observed (0.4% edoxaban 30 mg daily; 1.3% edoxaban 30 mg twice daily; 0.4% edoxaban 60 mg daily; 1.1% edoxaban 60 mg twice daily; 1.6% warfarin). These data helped investigators chose the edoxaban 30-and 60-mg doses for the phase III investigation.
The ENGAGE AF-TIMI 48 trial was a double-blind, double-dummy, non-inferiority trial that randomized 21,105 patients to receive high-dose edoxaban (60 mg daily), low-dose edoxaban (30 mg daily), or warfarin titrated to a goal INR 2-3 [28] . Subjects were enrolled with documented NVAF with a CrCl greater than 30 ml/min. The mean CHADS2 score was 2.8 in each arm representing a moderate-to-severe risk population for the occurrence of the composite primary outcome, determining that dose adjustment of edoxaban may be required in patients with low body weight (B60 kg) due to a higher incidence of all bleeding [35] . Pooled analysis of phase I and II trials also suggested that renal insufficiency (defined as CrCl 30-50 ml/min) and concomitant P-gp inhibitor treatment may also influence bleeding risk [36] . Concomitant aspirin administration may also be an important covariate for bleeding events, but this finding has not been shown to be statistically significant [35] . Overall, in phase II trials, edoxaban 30 and 60 mg once daily had rates of bleeding similar to or less than warfarin, produced treatment emergent adverse events similar to warfarin, and produced no significant difference in the incidence of hepatic enzyme elevations [31, 37] . From these trials, and results from pooled analyses, the once-daily edoxaban doses (30 and 60 mg) were selected for further investigation and comparison with warfarin for stroke prevention in patients with NVAF in the phase III ENGAGE AF-TIMI 48 trial [38] . Additionally, an edoxaban dose reduction (half dose) was recommended in patients with moderate renal impairment (CrCl 30-50 ml/ min), body weight B60 kg, and in patients taking strong P-gp inhibitors [36] .
In the ENGAGE AF-TIMI 48 trial, the principal safety endpoint was adjudicated major bleeding (defined by the International Society on Thrombosis and Haemostasis) [28] .
Other pertinent safety endpoints included any bleeding that was fatal, life-threatening, intracranial, or gastrointestinal, as well as any clinically relevant non-major bleeding (CRNMB), or the combination of any major or CRNMB. Both doses of edoxaban were superior to warfarin with respect to all significant bleeding outcomes including major, life-threatening, CRNMB, minor, and the combination of major or CRNMB. The annualized rates of major bleeding were 3.43% with warfarin, 2.75% with high-dose edoxaban (HR 0.80; 95% CI 0.71-0.91; p\0.001), and 1.61% (HR 0.47; 95% CI 0.41-0.55; p\0.001) with low-dose edoxaban (Table 4 ) [28] . With regards to the rate of gastrointestinal bleeding, low-dose edoxaban maintained superiority over warfarin (HR 0.67; 95% CI 0.53-0.83; p\0.001), however high-dose edoxaban was associated with higher rates of gastrointestinal bleeding compared to warfarin (HR 1.23; 95% CI 1.02-1.50; p = 0.03). The rates of non-bleeding adverse events were similar in the three treatment groups. Overall, edoxaban (both high and low-dose) was shown to be superior to dose-adjusted warfarin in almost all major bleeding outcomes, and this superiority was maintained in the subgroup of patients with a CrCl \95 ml/min, as well as those who received a dosage reduction at randomization.
In an indirect treatment comparison analysis of the NOACs for stroke prevention in NVAF, some differential safety effects were discovered with edoxaban (both high-and low-dose) and the other agents [39] . 
Venous Thromboembolism Prophylaxis
Edoxaban has not been FDA-approved for prophylaxis following orthopedic surgery.
Most clinical studies have used comparators that are known to be inferior, unavailable in the United States, or never studied in phase III trials. The dose finding study for orthopedic surgery evaluated edoxaban 5 mg (n = 88), 15 mg (n = 92), 30 mg (n = 88), and 60 mg (n = 88) [40] . This multicenter, placebo-controlled trial randomized 523 patients following total knee arthroplasty. The occurrence of any thrombotic event (PE and DVT) was reduced with higher doses (29.5, 26.1, 12.5, 9.1%) versus placebo arm (48.3%). This dose-ranging trial helped establish the edoxaban doses to pursue in future phase III orthopedic prophylaxis trials. Three Japanese phase III trials were conducted with edoxaban for the prevention of VTE in the STARS Table 4 Efficacy and safety of edoxaban in atrial fibrillation [28] ENGAGE-AF TIMI 48 trial The safety of edoxaban for the prevention of VTE following orthopedic surgery was also assessed. In a Japanese patient population following total knee arthroplasty, edoxaban at doses of 5, 15, 30, and 60 mg once daily for 11-14 days produced no difference in major or CRNMB versus placebo (1.9-4.7% in edoxaban groups versus 3.9% in placebo group) [40] . The incidence of treatment-related all bleeding events (major, CRNMB, and minor) was significantly increased in the edoxaban 60 mg once-daily group compared with placebo (17 vs.
6.9%, respectively; p = 0.025), but was not increased with the other edoxaban doses (5.8, 10.4, and 10.7% with edoxaban 5, 15, and 30 mg once daily, respectively) [40] . Edoxaban at doses of 15, 30, 60, or 90 mg once daily for 7-10 days produced no significant difference in major and/or CRNMB versus dalteparin sodium (initially 2500 IU, followed by 5000 IU) once daily in a Caucasian population following total hip replacement, and had a comparable incidence of major and CRNMB versus subcutaneous enoxaparin sodium 20 mg twice daily following total hip arthroplasty [45] .
Treatment emergent adverse events with edoxaban were similar to the comparator groups in all trials and there was no indication of hepatotoxicity. Overall, in phase II studies, edoxaban 30 mg once daily appeared to be well tolerated in both total knee and total hip arthroplasty and led to that dose being utilized for phase III testing.
Regarding safety, STARS J-4, J-V, and E-3 compared edoxaban 30 mg once daily to enoxaparin 20 mg twice daily (standard dosing in Japan), no significant difference in major and CRNM bleeding events was seen (major and CRNMB occurred in 6.2, 3.4, and 2.6% in the edoxaban groups in the STARS E-3, J-4 and J-V trials, respectively) [41] [42] [43] . However, these studies were generally underpowered to detect small differences in bleeding rates and the dosing of enoxaparin 20 mg twice daily may not allow extrapolation of these studies to other regions. Elevations in serum aminotransferase levels had a low incidence within the edoxaban groups and occurred less often than within the enoxaparin groups, a finding consistent with the results of a retrospective comparison between edoxaban, fondaparinux, and
Venous Thromboembolism Treatment
The Hokusai-VTE trial was a double-blind, non-inferiority trial that compared the safety and efficacy of edoxaban in the treatment of VTE [29] . Investigators randomized 8292 patients to receive edoxaban 30 or 60 mg The primary safety outcome measured was the incidence of major or CRNMB [29] . 
CONCLUSIONS
Edoxaban has emerged as an alternative to an ever-growing class of selective oral anticoagulants. It has been shown to be a safe and effective option for the prevention of stroke in the setting of NVAF and the treatment of VTE. Edoxaban has several clinical advantages including a once-daily regimen, the lack of need for bridging or routine therapeutic monitoring, and absence of food-drug interactions. Renal function and P-gp drug interactions will challenge its acceptance as an alternative to traditional and other novel anticoagulants.
